Table 1.
Descriptive of diffuse-type TGCT patients receiving imatinib mesylate treatment.
| Patients N (%) | |
|---|---|
| Total | 62 (100) |
| Median age at diagnosis (IQR), yrs. | 39 (31–53) |
| Median time from diagnosis to start IM (IQR), yrs. | 3.5 (1–8) |
| Sex | |
| Male | 23 (37) |
| Female | 39 (63) |
| Tumor location | |
| Knee | 35 (56) |
| Ankle | 11 (18) |
| Hip | 6 (10) |
| Foot | 4 (6) |
| Shoulder | 1 (2) |
| Elbow | 1 (2) |
| Head and Neck | 2 (3) |
| Wrist | 2 (3) |
| Surgery before start IM | |
| None | 15 (24) |
| 1–2 | 24 (39) |
| 3–4 | 13 (21) |
| >4 | 10 (16) |
| Median N of surgeries (range) | 2 (1–9) |
| Median time since last surgery (range), mo. | 23 (1–192) |
| Disease status | |
| Locally advanced | 20 (32) |
| Recurrence after surgery | 39 (63)* |
| Metastatic disease | 3 (5) |
Abbreviations: TGCT = Tenosynovial Giant Cell tumor, IM = imatinib mesylate, N = Number of patients, mo = months, yrs = years. *One of the locally recurrent patients progressed to metastatic disease.